Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide

    PRINCETON, N.J., Jan. 9 /CNW/ -- Novo Nordisk, a healthcare company with
an 84-year history of innovation and achievement in diabetes care, today
announced the appointment of Alan C. Moses, M.D. as vice president, chief
medical officer worldwide. Moses is currently the chief medical officer of
Novo Nordisk Inc., the company's U.S. affiliate.
    "Alan has the unique talent to integrate the science of discovery with
new drug development -- a critical asset that will deepen Novo Nordisk's
leadership position in changing diabetes," said Mads Krogsgaard Thomsen,
executive vice president and chief science officer for Novo Nordisk A/S. "The
broadening of Novo Nordisk's diabetes therapeutic portfolio with the
development of liraglutide and other novel molecules in the pipeline, and the
increasing importance of the U. S. to the Novo Nordisk business, requires a
leader with clinical and research expertise to assume the role of chief
medical officer."
    In the newly expanded role, Moses will work closely with senior
colleagues in Denmark to serve as the principle voice of clinical science for
the company worldwide, providing clinical and medical affairs expertise.
    "Novo Nordisk and the diabetes community in the U.S. have been fortunate
to have Alan lead the efforts for the company in changing diabetes, and now,
with his expanded responsibilities, the world will benefit from Alan's passion
for research and advocacy for finding better ways for people to live with the
disease," said Dr. Henrik Rasmussen, vice president of clinical development,
medical and regulatory affairs, Novo Nordisk Inc.
    Moses was formerly senior vice president and chief medical officer at the
Joslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vice
president of medical affairs and since then has also assumed responsibility
for clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Moses
spent 23 years at Harvard Medical School-affiliated institutions where he rose
to the rank of Professor of Medicine. He has written more than 100 peer-
reviewed articles on the treatment of diabetes and has been recognized both
locally and nationally for his research in diabetes and growth factors.
    Moses received a Bachelor of Science from Duke University and a Medical
Doctorate from Washington University School of Medicine prior to training at
Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda,
Md., and Tufts-New England Medical Center in Boston. He is board certified by
the American Board of Internal Medicine and has a subspecialty certification
in Endocrinology and Metabolism.
    About Novo Nordisk
    Novo Nordisk is a healthcare company with an 84-year history of
innovation and achievement in diabetes care. The company has the broadest
diabetes product portfolio in the industry, including the most advanced
products within the area of insulin delivery systems. In addition to diabetes
care, Novo Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment to
economic success, environmental soundness, and social responsibility to
employees and customers. With headquarters in Denmark, Novo Nordisk employs
more than 25,800 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO'. For global information, visit; for
United States information, visit

For further information:

For further information: Sean Clements, +1-609-514-8400, for Novo
Nordisk Web Site:        

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890